Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 8,44 € (+6,03%). La mediana è 8,17 € (+2,64%).
| Acquista |
15 |
| Mantieni |
27 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
BetterHelp and Sophia Bush launch The Permission Project to address women's mental health
BetterHelp launched The Permission Project, a therapist-developed initiative partnered with Sophia Bush that provides a Rewrite Guide, 10,000 hours of free therapy and a $100,000 investment in therapists focused on women’s mental health. The program is based on research identifying social tensions—like being ambitious but likeable—that correlate with rising anxiety and depression among women and offers actionable steps to counter them. Bush, who contributed to the project, emphasizes systemic causes of women's unrecognized labor and the need for cultural change alongside individual support. » Altro su forbes.com
Teladoc Health appoints Michael Grasher as chief financial officer
Teladoc Health has appointed Michael Grasher as CFO, effective immediately. Grasher has more than 30 years of experience in the insurance and financial services sector, including over 12 years in CFO roles at companies such as IFG Companies, Fortegra and AMERISAFE, and he also spent many years in equity research. » Altro su de.investing.com
Teladoc Health appoints Mark V. Anquillare to the board of directors
Teladoc Health has appointed Mark V. Anquillare, former president and COO of Verisk Analytics, to its board of directors. He will serve on the audit and compensation committees and brings more than 30 years of experience in finance and leadership roles, including overseeing Verisk’s 2009 IPO. Anquillare also sits on several other boards; Teladoc Health provides virtual healthcare services through partnerships with insurers, employers and health systems. » Altro su de.investing.com
Teladoc reports revenue decline and cuts annual forecast – stock falls sharply
Teladoc reported Q2 revenue of $606.9 million, missing the analyst consensus of about $615 million, while adjusted EPS of -$0.21 beat expectations. Consumer segment BetterHelp shrank 12% to $212.6 million. For Q3 management expects revenue of $569–609 million and lowered the full-year guidance to $2.36–2.45 billion (previously $2.48–2.58 billion), which weighed heavily on the stock in premarket trading. CEO Chuck Divita cited provider capacity constraints as the reason for weaker revenue realization; over the past six months there have been only insider sales. » Altro su de.investing.com
Teladoc plunges about 24% after Q2 results and weak outlook
Teladoc reported a Q2 EPS loss of -$0.21 with revenue of $606.9 million, missing consensus. The Q3 outlook of $569–609 million is well below the $629 million consensus, and the full-year loss forecast was lowered to -$1.00 to -$0.75. The combination of a revenue miss, reduced guidance and continued drag from the BetterHelp segment triggered the sharp share decline. Investors are now awaiting management comments on the conference call for signs of a return to revenue growth. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 534,21 Mln | 0,08% |
| Utile lordo | 366,25 Mln | 2,15% |
| Utile netto | -23,78 Mln | 43,63% |
| EBITDA | 61,03 Mln | 54,17% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,46 Mld € |
Numero di azioni | 182,29 Mln |
Massimo/minimo a 52 settimane | 8,97 € - 3,99 € |
| Dividendi | No |
Beta | 1,97 |
Rapporto P/E | -10,25 |
Rapporto PEG | -0,25 |
Rapporto P/B | 1,24 |
Rapporto P/S | 0,65 |
Profilo aziendale
Teladoc Health, Inc. fornisce servizi sanitari virtuali negli Stati Uniti e a livello internazionale. L'azienda offre un portafoglio di servizi e soluzioni che coprono condizioni mediche non urgenti, episodiche, croniche e complesse, tra cui diabete, ipertensione, malattia renale cronica, cancro, insufficienza cardiaca congestizia e disturbi della salute mentale. Propone una serie di programmi e servizi, tra cui soluzioni di telemedicina per l'assistenza primaria e specialistica, gestione delle patologie croniche, servizi medici specialistici, soluzioni per la salute mentale e servizi di piattaforma e programmi. L'azienda si rivolge a datori di lavoro, piani sanitari, ospedali e sistemi sanitari, compagnie assicurative e di servizi finanziari, oltre che a singoli utenti. I suoi prodotti e servizi sono offerti con i marchi Teladoc, Livongo e BetterHelp. In precedenza la società era nota come Teladoc, Inc. e ha cambiato denominazione in Teladoc Health, Inc. nell'agosto 2018. La società è stata costituita nel 2002 e ha sede a Purchase, New York.
| Nome | Teladoc Health |
| CEO | Charles Divita |
| Sede centrale | New York,
ny Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Fornitori e servizi sanitari |
| Quotazione in borsa | 30/06/2015 |
| Dipendenti | 5124 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | TDOC |
London Stock Exchange | 0LDR.L |
XETRA | 4LL.F |
Frankfurt | 4LL.F |
Düsseldorf | 4LL.DU |
London | 0LDR.L |
SIX | 4LL.SW |
München | 4LL.MU |